OmniComm Systems has announced that it has been selected by a leading European Contract Research Organization (CRO), to provide eClinical solutions for a pivotal phase III study in rheumatoid arthritis (RA).
Phase III clinical studies serve to establish the safety and efficacy of investigational new drugs, and are the last step prior to review for approval by the regulatory authorities. This particular RA study is expected to last 48 months and enroll close to 300 patients in 20 sites located in Europe.
Stephen Johnson, COO of OmniComm, said: We are very excited to be working again with this CRO on this pivotal study. We appreciate their ongoing trust in us and will continue to deliver superior products and services to them. We are also very excited about our continued expansion into the European marketplace. We have recently opened up another office in the United Kingdom, OmniComm Ltd., which will allow us to broaden our service and support offering even further.
Content from our partners
